Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today provided the following letter to shareholders from ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of 11.1%, reaching US$145.53 billion in 2024 and an impressive US$246.

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports ...

Investors and interested parties are advised that the forward-looking statements in this announcement are subject to various factors that could cause actual results to differ materially from those ...